Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

NCT01220128 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01220128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01220128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
April 11, 2011
Completion date
November 14, 2014
Enrollment
66 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast